Maureen Okafor, MD MPH

PGY-2 IM Resident Physician @SouthBKHealth, aspiring GI 🩺

[Maureen Okafor, MD MPH @okaformo]

Excited to share that my 5 first-author abstracts will be featured at #ACG2026 this October! I'm super grateful to my mentors and collaborators. Happy to learn and contribute to advances in GI. @AmCollegeGastro @AmerGastroAssn @AAFG_2021

Nashville, see you in the fall! 🎉🍂🎸

[Maureen Okafor, MD MPH @okaformo]

Thank you @AAFG_2021 @DDWMeeting for highlighting our work. Let's thoughtfully consider older age, black race, longer hospital stay, hospital cost and chronic comorbidities as factors linked with in-hospital C. diff colitis. How can we improve clinical outcomes in these patients?

[African Association Of Future Gastroenterologists @AAFG_2021]

Join @okaformo at @DDWMeeting

📌 Internal Medicine Resident

#FutureGastroenterologist
#DDW2026

[Maureen Okafor, MD MPH @okaformo]

Honored to receive Outstanding Poster Presenter Award for our poster on primary gastric SCC at #ACG2025 this week. Heartfelt thanks to my amazing co-authors, colleagues and mentors, @AmCollegeGastro, @blackingastro, @SouthBKHealth and for new friends made! #GITwitter #MedTwitter

[Maureen Okafor, MD MPH @okaformo]

Last week at DDW2025 and ABGH Summit was truly phenomenal! Exciting to meet and interact with great minds.

[Maureen Okafor, MD MPH @okaformo]

Excited to share our work on technology literacy and access in Alzheimer's dx research. Hoping this work provides a better understanding of the role of digital health in research participation, especially in remote areas. #Technology #DigitalHealth #SDOH
https://t.co/dAC9DSV4z9

[Maureen Okafor, MD MPH @okaformo]

One of many steps toward drug discovery and repurposing for prodromal Alzheimer's disease. Really glad to share this work.

[@BrainComms @braincomms]

Hajjar et al. report that candesartan treatment may provide favourable effects on brain amyloid accumulation and executive function in non-hypertensives with prodromal #AlzheimersDisease. @JoeyYang100 @okaformo @EmoryBrain @EmoryMedicine https://t.co/A8uLBOz1UT

[Maureen Okafor, MD MPH @okaformo]

WEBINAR THIS WEEK: Treatment of sleep disturbance for dementia prevention: key considerations for trial design targeting insomnia and obstructive sleep apnea. Join the conversation this Thursday! Register here: https://t.co/wilAyYvIJh
@ISTAART @ClinTrialsPIA @SleepPIA

[Maureen Okafor, MD MPH @okaformo]

Very pleased to share our work on differences in plasma and CSF AD biomarkers by race, genetic ancestry, and vascular and neighborhood factors.

[JAMA Network Open @JAMANetworkOpen]

Plasma biomarkers in #AlzheimerDisease were lower in African American patients compared with White patients in Atlanta, based on self-reported race but not genetic ancestry and independent of cognitive, vascular comorbidity, and APOE4 status. #OAResearch https://t.co/nVaMi1BJiQ

[Clinical Trials Advancement and Methods PIA @ClinTrialsPIA]

Sex and gender differences in clinical trials on November 3rd, 2022
Register today at:
https://t.co/CkCsh38wyv

[Clinical Trials Advancement and Methods PIA @ClinTrialsPIA]

We are eager to spotlight our members' work in trials! Let us know of your new pubs, grants, and current projects!
Include @ClinTrialsPIA in your posts and we will retweet, d/m us, or email the PIA Communication Director at [email protected] with updates to share!

[Clinical Trials Advancement and Methods PIA @ClinTrialsPIA]

Registration is now open for the November 17th webinar with CTAM and @SleepPIA:
https://t.co/CkCsh2QV9V

[Clinical Trials Advancement and Methods PIA @ClinTrialsPIA]

Get to know CTAM PIA EC
Chair: Erin Abner @ErinAbnerPhD
Vice Chair: Rema Raman
Programs:  Carla Abdelnour Ruiz @carlaabdelnour
Communication: Elizabeth Rhodus @DrERhodus
Early Career Rep: Vee Bala @vee_0111
Maureen Okafor @okaformo
Past Chair:  Ruth Peters @ruth_peters_

[Clinical Trials Advancement and Methods PIA @ClinTrialsPIA]

Measuring Clinically Meaningful Change in Preclinical AD Trials: New Approaches & Challenges
Wednesday, 8/17/22, 12-1p.m. CDT
Moderator: Erin Abner, Roosmarijn Jutten, Kathleen Welsh-Bohmer
Panelists: Mark Dubbelman, Kathy Liu, Lon Schneider, Eric Siemers
https://t.co/ntVVEWDfvC

[Maureen Okafor, MD MPH @okaformo]

Join us for the @ISTAART CTAM PIA and Diversity PIA webinar on May 23rd. Looking forward to a dynamic discussion of sustained diverse representation in AD clinical trials. #ClinicalTrialsPIA #DiversityPIA @alzassociation Register here: https://t.co/XOnhCrF1HA

[Prof Cath Mummery @cathmummery]

Don't miss this opportunity to hear from the experts! The #clinicaltrialsPIA workshop focuses on methods to improve interim decision-making in clinical trial designs: keynote! Dr. Scott Emerson “Learning from mistakes in interim analyses in AD clinical trials”.

[Maureen Okafor, MD MPH @okaformo]

@dem_researcher @volkmer_anna @wagnersbrum @ajehrenberg @dorsmanka @ALZ_Rebecca Thanks! @dem_researcher @BetterResearch It was such a good discussion and a great opportunity to connect with you all on the #AAIC21 Highlights.😊 By the way, my correct handle is @okaformo. The one up there is probably an innocent bystander 😊

[RikOssenkoppele @RikOssenkoppele]

Pleased to share our latest work showing that #Tau #PET correlates with different #Alzheimer’s disease-related features compared to #CSF and #plasma p-tau biomarkers, https://t.co/XKJ7b2AlFR. @EmboMolMed
@biofinder_study @AlzheimerAms @NiklasMattsson4 @PhilipAlz @OskarHansson9

[Claire Sexton @claire_e_sexton]

This Thursday! Sign up at https://t.co/rA0aCH8KSs to hear insights into atypical AD biomarkers, and atabecestat trials in preclinical AD. @okaformo, @carlaabdelnour, @DrNeuroChic #ClinicalTrialsPIA #ISTAART

[JAMA Network Open @JAMANetworkOpen]

https://t.co/PD1VDIAQFO